Regenxbio Reports Positive Phase III Data for RGX-202 Gene Therapy
Regenxbio (RGNX) reported positive results from the pivotal portion of its AFFINITY DUCHENNE trial, with 93% of patients achieving above 10% microdystrophin expression. The data showed strong biomarker responses and functional improvements in Duchenne muscular dystrophy patients.
Tickers: $RGNX